Valuation: Sera Prognostics, Inc.

Market Cap 79.29M 69.98M 66.21M 60.04M 113M 7.61B 114M 794M 306M 3.89B 298M 291M 12.5B P/E 2026 *
-3.06x
P/E 2027 * -3.76x
Enterprise Value 79.29M 69.98M 66.21M 60.04M 113M 7.61B 114M 794M 306M 3.89B 298M 291M 12.5B EV / Sales 2026 *
352x
EV / Sales 2027 * 41.2x
Free-Float
85.71%
Yield 2026 *
-
Yield 2027 * -
1 day-0.50%
1 week-5.63%
Current month-5.19%
1 month-2.90%
3 months+11.05%
6 months+8.65%
Current year-31.86%
1 week 2
Extreme 2
2.14
1 month 1.96
Extreme 1.9603
2.2
Current year 1.56
Extreme 1.56
3.85
1 year 1.56
Extreme 1.56
3.95
3 years 1.37
Extreme 1.37
12.36
5 years 1.1
Extreme 1.1
12.36
10 years 1.1
Extreme 1.1
15.5
Manager TitleAgeSince
Chief Executive Officer 52 01/06/2023
Director of Finance/CFO 47 31/08/2026
Chief Tech/Sci/R&D Officer - 01/01/2022
Director TitleAgeSince
Chairman 74 20/04/2011
Chairman 58 08/06/2023
Director/Board Member 59 01/11/2011
Date Insider Type Main position Quantity % Market Cap. Importance
10/9/26 Sell

Chief Executive Officer

-7,022 0.0182%
10/9/26 Sell

General Counsel

-2,190 0.0057%
10/9/26 Sell

Chief Technology Officer

-486 0.0013%
Change 5-day change 1-year change 3-year change Capi.($)
-0.50%-5.63%-34.10%+8.06% 79.29M
-1.13%+1.06%+7.56%+59.07% 672B
-0.23%-0.53%-3.03%+64.44% 79B
+3.83%+0.52%+115.35%+1,153.19% 65.06B
+1.06%-2.73%+7.48%+128.21% 63.15B
-0.62%+1.89%-22.66%-7.82% 46.1B
-0.55%-4.49%-1.78%+67.31% 44.76B
+0.27%-2.50%+8.36%+20.63% 30.23B
-0.58%-0.06%+32.75%+53.79% 25.78B
-0.67%-1.61%-65.23%-59.84% 24.12B
Average +0.23%-0.81%+4.47%+148.70% 104.99B
Weighted average by Cap. -0.40%+0.45%+10.68%+124.87%

Financials

2026 *2027 *
Net sales 225K 199K 188K 170K 319K 21.59M 323K 2.25M 869K 11.02M 845K 826K 35.48M 1.92M 1.7M 1.61M 1.46M 2.73M 185M 2.76M 19.28M 7.43M 94.32M 7.23M 7.07M 304M
Net income -33.93M -29.95M -28.33M -25.7M -48.17M -3.26B -48.65M -340M -131M -1.66B -127M -125M -5.35B -29.1M -25.68M -24.3M -22.04M -41.31M -2.79B -41.72M -291M -112M -1.43B -109M -107M -4.59B
Net Debt - -
Logo Sera Prognostics, Inc.
Sera Prognostics, Inc. is a women's health diagnostic company utilizing its proprietary proteomics and bioinformatics platform, and significant data resources to enhance maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. It has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. Its commercial product, the PreTRM test, is a validated, commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation that provides a prediction of the expectant mother’s risk of delivering spontaneously before 37 weeks’ gestation.
Employees
72
Date Price Change Volume
29/09/26 US$2.010 -0.50% 4,341
28/09/26 US$2.020 -0.98% 6,910
25/09/26 US$2.040 -3.32% 12,771
24/09/26 US$2.110 +2.43% 5,357
23/09/26 US$2.060 -3.29% 13,907
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.010USD
Average target price
5.500USD
Spread / Average Target
+173.63%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SERA Stock